Dr. Lal PathLabs is currently trading at Rs. 2740.15, up by 40.30 points or 1.49% from its previous closing of Rs. 2699.85 on the BSE.
The scrip opened at Rs. 2725.00 and has touched a high and low of Rs. 2746.05 and Rs. 2683.15 respectively. So far 1309 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3645.00 on 10-Oct-2024 and a 52 week low of Rs. 2168.80 on 19-Apr-2024.
Last one week high and low of the scrip stood at Rs. 2746.05 and Rs. 2405.45 respectively. The current market cap of the company is Rs. 22905.39 crore.
The promoters holding in the company stood at 53.91%, while Institutions and Non-Institutions held 39.99% and 6.10% respectively.
Dr. Lal PathLabs has introduced Amyloid typing by laser capture microdissection & mass spectrometry - a revolution test for accurately identifying different types of Amyloid proteins. With this launch, the company becomes the first diagnostic chain in South Asia to offer this highly specialized test. The company has launched this test, under the guidance of National Amyloidosis Centre, London (UK).
Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 6951.85 |
Max Healthcare Inst | 1068.00 |
Narayana Hrudayalay | 1787.40 |
Aster DM Healthcare | 505.25 |
Global Health | 1214.75 |
View more.. |